Other MS patients, a minority, have a form of the disease that features gradually increasing progressive disability from onset—so-called primary progressive MS (PPMS). While effective disease ...

"I'm just, I'm frustrated," said Rhonda Mirabella.Rhonda Mirabella is masking her emotions. She's hurt and angry with the ...

National Multiple Sclerosis Society: "FDA Approves Ocrevus™ (ocrelizumab) for People with Primary Progressive MS or Relapsing MS -- First Disease-Modifying Therapy for Primary Progressive MS ...

This exploratory study assessed the safety and clinical benefit of masitinib in the treatment of primary progressive MS (PPMS) or relapse-free secondary progressive MS (rfSPMS). Methods ...

Sanofi is also running a fourth phase 3 trial called PERSEUS in patients with primary progressive MS (PPMS). Earlier this year, it abandoned its development in another neuromuscular disorder ...

clinically isolated syndrome relapsing-remitting MS secondary progressive MS primary progressive MS There’s no one set timeline or course of MS, but knowing the type can help you understand and ...

A chronic and progressive neurological condition that affects millions across the world, multiple sclerosis (MS) can be a ...

Higher blood levels of bile acids, molecules that aid fat absorption in the gut, are linked to slower MS progression, per ...

A new drug for people who have one of the worst forms of multiple sclerosis aims to make treatment much easier for patients. Ocrevus is a medicine commonly used to treat primary progressive MS ...

often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher ...

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative co ...

Should the topline data continue to show a neuroprotective effect and the Phase 2 trial meets its primary and key secondary endpoints, we may also be able to position the drug as the first oral ...